These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17845945)

  • 1. Update on osteoporosis management in long-term care: focus on bisphosphonates.
    Kamel HK
    J Am Med Dir Assoc; 2007 Sep; 8(7):434-40. PubMed ID: 17845945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S
    Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonates treatment in patients with osteoporosis].
    Rizzoli R
    Ther Umsch; 2012 Mar; 69(3):173-81. PubMed ID: 22403110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Post hip fracture care].
    Tandjung R; Rosemann T
    Praxis (Bern 1994); 2011 Jul; 100(15):917-21. PubMed ID: 21792807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A; Adachi J; Olszynski W
    CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Reginster JY
    Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.